Anna Sansone1, Nicoletta De Rosa2, Pierluigi Giampaolino3, Maurizio Guida4, Antonio Simone Laganà5, Costantino Di Carlo6. 1. Department of Public Health and Preventive Medicine, University of Naples Federico II, Via Sergio Pansini, Naples, Italy. 2. Department of Neurosciences and Reproductive Sciences, University of Naples Federico II, Via Sergio Pansini, Naples, Italy. 3. Department of Public Health and Preventive Medicine, University of Naples Federico II, Via Sergio Pansini, Naples, Italy. pgiampaolino@gmail.com. 4. Department of Obstetrics and Gynecology, University of Medicine and Surgery of Salerno, Via Allende, Salerno, Italy. 5. Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, Piazza Biroldi 1, 21100, Varese, Italy. 6. Department of Experimental and Clinical Medicine Unit of Obstetrics, Gynecology University of Catanzaro "Magna Graecia", Viale Europa, Catanzaro, Italy.
Abstract
PURPOSE: Progestins are successfully employed as treatment for endometriosis. Our study evaluates the effects of the etonogestrel (ENG) implant on pelvic pain, quality of life, and sexual function in women requiring long-term reversible contraception and presenting ovarian cysts of probable endometriotic origin. METHODS: We enrolled 25 women asking for contraception with the ENG implant and presenting a cyst with the ultrasound features of an endometrioma and pain symptoms. Patients were interviewed on pain symptoms (dysmenorrhea, dyspareunia, dyschezia, and dysuria) using a VAS score (0-10), on quality of life (QoL) using the Short Form-36 questionnaire, and on sexual activity using the Female Sexual Function Index (FSFI) questionnaire before inserting the implant (T0) and after 6 (T1) and 12 months (T2). RESULTS: We found a significant decrease in dysmenorrhea and dyspareunia VAS scores comparing baseline scores to 6 and 12 months. After 12 months, the bodily pain, general health, vitality, social functioning, and mental health domains of the QoL score were significantly improved. The total FSFI score results increased in comparison with baseline both at 6 and 12 months. In particular, we highlighted a significant improvement in desire, satisfaction, and pain domains already at 6 months; the arousal domain improved only after 12 months. Finally, mean diameters of endometrioma-like cysts were not changed after 12 months of treatment. CONCLUSIONS: Etonogestrel implants seem to be able to reduce pelvic pain, improve sexual function, and quality of life in patients with ovarian cysts suspected of endometriotic origin.
PURPOSE: Progestins are successfully employed as treatment for endometriosis. Our study evaluates the effects of the etonogestrel (ENG) implant on pelvic pain, quality of life, and sexual function in women requiring long-term reversible contraception and presenting ovarian cysts of probable endometriotic origin. METHODS: We enrolled 25 women asking for contraception with the ENG implant and presenting a cyst with the ultrasound features of an endometrioma and pain symptoms. Patients were interviewed on pain symptoms (dysmenorrhea, dyspareunia, dyschezia, and dysuria) using a VAS score (0-10), on quality of life (QoL) using the Short Form-36 questionnaire, and on sexual activity using the Female Sexual Function Index (FSFI) questionnaire before inserting the implant (T0) and after 6 (T1) and 12 months (T2). RESULTS: We found a significant decrease in dysmenorrhea and dyspareunia VAS scores comparing baseline scores to 6 and 12 months. After 12 months, the bodily pain, general health, vitality, social functioning, and mental health domains of the QoL score were significantly improved. The total FSFI score results increased in comparison with baseline both at 6 and 12 months. In particular, we highlighted a significant improvement in desire, satisfaction, and pain domains already at 6 months; the arousal domain improved only after 12 months. Finally, mean diameters of endometrioma-like cysts were not changed after 12 months of treatment. CONCLUSIONS:Etonogestrel implants seem to be able to reduce pelvic pain, improve sexual function, and quality of life in patients with ovarian cysts suspected of endometriotic origin.
Entities:
Keywords:
Contraception; Endometriosis; Etonogestrel implant; Pelvic pain; Quality of life
Authors: Mauricio S Abrao; Eric Surrey; Keith Gordon; Michael C Snabes; Hui Wang; Horia Ijacu; Hugh S Taylor Journal: BMC Womens Health Date: 2021-06-16 Impact factor: 2.809
Authors: Gaetano Riemma; Antonio Simone Laganà; Antonio Schiattarella; Simone Garzon; Luigi Cobellis; Raffaele Autiero; Federico Licciardi; Luigi Della Corte; Marco La Verde; Pasquale De Franciscis Journal: Int J Mol Sci Date: 2020-02-07 Impact factor: 5.923